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Determination of Rh, Kell, Duffy and Kidd phenotypes in addition to ABO is
used to prevent the alloimmunization to red blood cells (RBCs) antigens and
as part of the antibody identification process in patients with β Thalassemia.
However, phenotyping in these patients can be time consuming and difficult
to interpret. In these situations, it would be valuable to have an alternative to
hemagglutination tests to determine the patient’s antigen profile. We used
PCR-RFLP to genotype such patients.
DNA was prepared from 50 patients with β Thalassemia who had been
phenotyped by routine hemagglutination, and tested for Kell, Kidd, Duffy/
GATA mutation by PCR-RFLP. RHD/non-D was analysed by PCR product size
associated to RHD gene sequence in intron 4 and exon 10/3’UTR. The
genotyping assays were performed without knowledge of phenotype results.
For RHD/non-D, 47 were RhD+ and RHD+/RHCE+, and 3 were RhD- and
RHD-/RHCE+. For Kell, 48 kk were K2K2 and 2 Kk were K1K2. For Duffy, of
44 samples that had normal GATA box, 8 Fy(a+b-) were FYA/FYA, 15
Fy(a+b+) were FYB/FYB, and 19 Fy(a+b+) were FYA/FYB; of the other 4
samples 3 were FYA/FYB and heterozygous GATA mutation, and 1 Fy(a-b-)
was FYB/FYB, homozygous GATA mutation. Two samples phenotyped as
Fy(a+b-) that had normal GATA , presented the 265T/298A  mutations and
two samples phenotyped as Fy(a-b+) were genotyped was FYA/FYB.. For Kidd
, 15 Jk(a+b) were JKA/JKA, 12 Jk(a-b+) were JKB/JKB, and 20 Jk(a+b+) were
JKA/JKB. Three samples phenotyped as JK(a+b+) were genotyped as JKB/JKB.
Genotype is more accurate than phenotype for determination of blood groups
in polytransfused patients with βThalassemia. Genotyping in these patients
can be helpful to select antigen-negative RBCs for transfusion.
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Introduction
The incidence of alloimmunization to RBC
antigens other than ABO and D is particularly
high in patients with hemoglobinopathies (1),
reaching up to 18% in patients with β
Thalassemia who have received transfusion(s)
(2-4). Alloimmunization may cause a variety of
problems and dilemmas in long-term medical
and transfusional management (5, 6). Most of
these problems pertain to finding appropriate
antigen-negative blood for transfusion to
alloimmunized patients.
Programs to prevent alloimmunization to
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RBC antigens have been designed and
implemented to provide antigen-matched RBC
transfusions to patients with Thalassemia,
particularly those who are alloimmunized and/
or in need of chronic transfusion support (7,
8). In addition to ABO, RBCs are phenotyped
for Rh, Kell, Duffy and Kidd prior to transfusion
aiming both to prevent the alloimmunization
to these RBC antigens, and as part of the
antibody identification process (9).
Cell typing is essential in sensitized
patients in order to confirm the identity of
suspected alloantibodies, and to facilitate the
identification of antibodies that may be formed
in the future.  However, accurate phenotyping
of RBCs from transfused patients with
Thalassemia is a very complex process due
to the presence of transfused donors RBCs in
the circulation of the recipient. Thus, in these
patients phenotyping can be time consuming
and difficult to interpret. It is also complicated
to type cells when a patient’s RBCs have a
positive direct antiglobulin test and no direct
agglutinating antibody is available.
The DNA technology led to the
understanding of the molecular basis of many
blood group antigens. The majority of blood
group polymorphisms are associated with a
single point mutation in the gene encoding
the protein carrying the blood group antigen
(10, 11). This knowledge allows the use of
DNA testing to predict the blood group
antigen profile of na individual, and that can
be used to overcome the limitations of
hemagglutination assays.
Several assays for blood group genotyping
of patients have recently been developed with
the goal of reducing risk or helping in the
assessment of the risk of hemolytic disease of
the newborn. However, these assays have not
been generally applied to the genotyping of
patients who have received recent or chronic
transfusion care.
The dilema of using DNA obtained from
a transfused patients’ white blood cells (WBC)
is that the donor leucocytes contained in the
transfused units could, at least theoretically,
interfere with genotyping results (12, 13, 14).
However, studies performed with patient’s
WBC samples have shown that these cells can
be used reliably to determine a blood group
polymorphism by polymerase chain reaction
(PCR)-based assays even when blood samples
from recently transfused patients are used as
the source of DNA (15, 16). This study
demonstrates that post-transfusion blood
samples can be safely used for genotyping
blood groups. That eliminates the need to use
current time-consuming and frequently
ineffective methods that involve separation of
patient reticulocytes from donor mature RBCs.
We performed genotype assays and
correlated the results with phenotype results for
the blood groups RH D, KEL, JK and FY using
WBCs from polytransfused patients with β
Thalassemia. We also report here that WBCs
can be reliably employed as source of DNA for
PCR-based assays for blood group genotyping
in transfused patients with β Thalassemia as
compared against PCR results obtained from
other cell source of DNA. Moreover, we
observed that genotype is more accurate than
phenotype for determination of blood groups
in polytransfused patients with β Thalassemia.
Methods
Samples: Blood samples and buccal
epithelial cells were collected from each patient
after informed consent was given to the health
care physician or specialized nurse.
Blood samples: We studied samples from
50 patients with β Thalassemia who have
been given transfusions of antigen-matched
RBC units at the Hemocentro (Unicamp,
Campinas, Brazil). These patients had been
transfused at least 3 occasions and their blood
samples were phenotyped at the time of each
transfusion. The most recent blood sample
from each patient was also genotyped for
RHD, KEL, JK and FY. Blood samples from
100 normal blood donors who had been
previously phenotyped for Rh, Kell, Kidd and
Duffy were tested as controls.
Buccal epithelial cells: Buccal epithelial
cells samples were tested for the patients
whom had phenotype/genotype
discrepancies. We obtained buccal epithelial
cells by wiping the mouth mucosa with a
cotton wool swab.
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Agglutination tests: At all times phenotypes
were determined by hemagglutination in gel
cards (Diamed AG, Morat, Switzerland) using
two anti-sera sources.
DNA preparation: DNA was extracted from
blood samples using either the phenol-
chloroform method (17) or the Easy DNA Kit
(Invitrogen, Carlsbad, CA) according to the
manufacturer’s recommendations. DNA from
buccal epithelial cells contained in the cotton
wool swabs was extracted by the Easy DNA Kit
according to manufacturer’s protocol #3.
Polymerase chain reaction (PCR)
amplification: The primers and amplification
conditions used, were the same as previously
published (15, 16). Briefly, the PCR was
Figure 1. RH D genotyping
performed with 100-200 ng of DNA, 50 pmole
of each primer, 2 nmole of each dNTP, 1.0 U
Taq DNA polymerase and buffer in a final
volume of 50 µl. The PCR analysis for the
presence of RHD was performed in two genomic
regions, intron 4 and exon 10, as previously
described (16). For intron 4, three primers
(RHI41, RHI42 and RHI43) yielded a product of
115 bp for RHD and 236 bp for RHCE. For exon
10, a common 5’primer (EX10F) was used for
both RHD and RHCE. When paired with the
RHD-specific 3’-untranslated region (UT)
primer (RHD3UT), it produced a product of
245 bp, and when paired with the RHCE-
specific 3’-UTR (RHCE3UT), it yielded a product
of 160 bp (Figure 1).
Figure 2. Kell genotyping
RHCE 236 bp
RHD 115 bp
← RHD 245 bp
← RHCE 160 bp
Intron 4 Exon 10
Rh+ Rh- Rh+ 50bp Rh+ Rh-
200 bp
100 bp
100 bp
156 bp
56 bp
100 bp
ladder PCR K2K2 K2K2 K1K2 K1K1
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RFLP analysis:  The PCR ampli f ied
products were digested overnight with the
appropr ia te res t r ic t ion enzymes (MBI
Fermentas, Amherst, NY or New England
Biolab, Beverly, MA), in a final volume of
20ml using 10ml of amplified product and
enzyme in 1x buf fer  according to
manufacturer’s instructions.
 The enzymes Bsm I, Mnl I and Ban I
were used to determine, respectively KEL 1/
KEL 2 (698C>T), JK A/JK B (838
A
>G) and FY
A/ FY B (125 G>A) (18-22). (Figures 2, 3, 4)
Furthermore, the Sty I enzyme was used to
distinguish between normal and mutated
GATA-1 binding motif (-33T>C), because the
GATA-1 binding site is critical for expression
of Fy
b
 protein in the red cell membrane (23)
(Figure 4).
Results
Correlation between phenotype and
genotype of the 50 patients with β Thalassemia
were as follows for each blood antigen
studied: Phenotype and genotype results from
the patients with β Thalassemia are shown in
table 1. Among the 50 patients, 5 had
phenotype/genotype discrepancies.
Figure 3. Kidd genotyping
Figure 4. Duffy genotyping
300 bp
200 bp
100 bp
85 bp
77 bp
61 bp
48 bp
100 bp
ladder PCR JKA/JKB JKB/JKB JKA/JKA
FYA/FYB Ban I
100 bp
ladder PCR FYA/FYB FYA/FYB FYB/FYB
GATA mutation Sty I
100 bp
ladder PCR M/M W/W
400 bp
300 bp
200 bp
100 bp
392 bp
306 bp
96 bp
86 bp
189 bp
108 bp
81 bp
61 bp
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Presence or absence of RHD: 47 of the 50
samples were both phenotyped and genotyped
as RhD-positive (had amplified product from both
RHD and RHCE) and 3 samples phenotyped and
genotyped as RhD-negative (had amplified
product from RHCE but not from RHD).
Kell: we observed 100% correlation
between phenotype and genotype results for
Kell: 48 samples phenotyped as k/k were
genotyped as K2/K2 and two samples
phenotyped as K/k were genotyped as K1/K2.
Kidd: phenotype/ genotype did not correlate
in 3 of the 50 samples, as they phenotyped as
Jk(a+b+) and genotyped as JKB/JKB.
Duffy: 44 samples had normal GATA box,
8 Fy(a+b–) were FYA/FYA, 15 Fy(a–b+) were
FYB/FYB, 19 Fy(a+b+) were FYA/FYB and two
samples phenotyped as Fy(a+b) were Fy
x
 and,
presented the 265T and 298A
 
mutations. Of the
other 4 samples 3 Fy(a+b–) were FYA/FYB and
heterozygous GATA mutation, 1 Fy(a–b–) was
FYB/FYB and homozygous GATA mutated. The
two discrepant samples phenotyped as Fy(ab+)
and were genotyped as  FYA/FYB, homozygous
GATA mutation.
Correlation between phenotype and genotype
of the 100 volunteer blood donors control:
In this group was observed an agreement
of 100% for all blood groups studied.
Genotypes results obtained on DNA from
buccal cells and WBCs from the 6 patients whom
had phenotype/genotype discrepancies:
In order to demonstrate the absence of
microchimerism in discrepant results, all 5
patients with phenotype/genotype discrepancies
results had the DNA from buccal cells tested by
PCR-RFLP, and the results were identical to those
obtained when tests were performed using DNA
from blood samples.
Discussion
This study shows the relevance of
performing molecular analysis for the
determination of blood groups in transfusion
dependent patients such as patients with β
Thalassemia. By employing PCR-RFLP assays
we have shown that as expected there is
mis typing when hemagglut inat ion is
performed to determine the blood group of
multitransfused patients. As observed in
genotype and phenotype results correlation
of the 50 transfused patients studied,
phenotype/genotype discrepancies were
found in 5 cases.
We confirmed previous study observations
that DNA prepared from blood samples
collected from a patient who has recently
Table 1: Genotyping results for, RH, KEL, KIDD and DUFFY  in samples from 50 patients with β Thalassemia
* Fy
x
 265T, 298
A
Genotype                             Phenotype
Rh System RhD+ RhD-
RHD+/RHCE+ 47 0
RHD–/RHCE+ 0 3
Kell System K+k+ K-k+
K1K2 2 0
K2K2 0 48
Kidd System Jk(a+b–) Jk(a+b+) Jk(a–b+)
JKA/JKA 15 0 0
JKA/JKB 0 20 0
JKB/JKB 0 3 12
Duffy System Fy(a+b-) Fy(a+b+) Fy(a-b+) Fy(a-b-)
FYA/FYA (T/T) 8 0 0 0
FYA/FYB (T/T) 0 19 2 0
FYA/FYB (T/C) 3 0 0 0
FYB/FYB (T/T) 2* 0 15 0
FYB/FYB (C/C) 0 0 0 1
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received a transfusion, can be used for blood
group genotyping without risk of detecting
microchimerism (16).
The relevance of performing molecular
tests in transfusion dependent patients is well
illustrated in the Duffy system.  In the presence
of nomal GATA-1 binding motif, phenotypes
and genotypes agree, but when the GATA-1
motif is mutated a pseudo-discrepancy is
observed. That is due to the absence of the FY
gene expression in the erythroid lineage.
However, patients carrying such phenotypes
do not need blood units of negative phenotype,
once that this protein is expressed in other
body tissues, thus recognized as self. This small
change in blood type requirement increases
the availability of special blood types for such
patiens. GATA mutation in our population has
only been associated with the FY B allele,
however, it has been found associated with
the FY A allele in population from Papua New
Guinea (24). Our study also identified two true
discrepant samples. Their hemagglutination
results were Fy(a–b+) and their genotype
results were FY A/FY B. Accordingly, DNA
samples obtained from buccal epithelial cells
confirmed the genotype obtained from the
blood sample. The phenotype performed in
segments of the transfused units further
confirmed that the Fy(ab+) reflected the donor’s
blood type. Three samples also presented
discrepancy in the Kidd typing. All 3 samples
phenotyped as Jk(a+b+) were genotyped as
JKB/JKB. The absence of JK A was confirmed
by genotyping DNA samples obtained from
buccal epithelial cells, and by performing
phenotyping in segments of the transfused
units, that the Jk(a+) reactivity was due to
donors RBCs in the patient’s circulation system.
These three patients could have been
immunized for Jk
a
 antigen because they were
receiving antigen-matched RBC units based in
the phenotyping interpretation.
As previously discussed, the seriousness
of the alloimmunization problem has led to
recommendations that patients with β
Thalassemia be transfused with blood of donors
whose RBC antigens are more closely matched
to those of the recipients (7-9). However,
accurate antigen typing in transfused patients
is a major problem due to the presence of
donor RBCs in patient’s circulation. Based on
our results and under the test conditions we
established, we recommend the addition of
blood group genotyping for transfused patients
to provide antigen-matched RBC transfusions.
However, caution in performing these tests and
interpreting results must be exercized, since
the PCR-based technique is prone to
contamination, and the presence of a particular
genotype may not be associated with that
antigen expression on the RBC’s membrane.
Such situations include, the detection of genes
with a silencing mutation in a location other
than that being analysed (e.g., point mutation
in the GATA box), the detection of a gene that
is silenced by na alteration of a gene encoding
protein with a modifying effect (e.g. Rhmod,
Rhnull), or the detection or nondetection of a
hybrid gene (25-29).
 
The possibility to have
na alternative to hemmaglutination tests to
determine the patient’s antigen profile should
be considered for patients with β Thalassemia
who need repeated transfusion therapy.
Genotipagem dos sistemas Kell, Duffy, Kidd
e RHD em pacientes com β Talassemia
Lilian Castilho, Maria Rios, Jordão Pellegrino Jr,
Maria H. M. Carvalho, Fernando L. Alberto, Sara
T.O. Saad, Fernando F. Costa
Sumário
A determinação dos fenótipos Rh, Kell, Duffy e
Kidd, associada ao ABO é utilizada para prevenir
a aloimunização a antígenos eritrocitários e
participam também no processo de identificação
de anticorpos nos pacientes com β talassemia.
Todavia, a fenotipagem desses pacientes é
trabalhosa e de difícil interpretação. Nesta
situação, deve ser avaliada uma alternativa ao
teste de hemaglutinação para determinar o
padrão antigênico dos pacientes.
Utilizamos para tal fim o método PCR-RFLP.
Foram preparados DNAs de 50 pacientes com β
talassemia que haviam sido anteriormente
fenotipados pela hamglutinação e testados para
Kell, Kidd, Duffy/GATA mutação por PCR-RFLP.
RHD/não-D foi analisado pelo tamanho do
produto, do PCR associado à seqüência do gene
RHD no intron 4 e exon 10/3’ UTR.
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Os testes de genotipagem foram realizados sem
o conhecimento dos resultados dos fenótipos.
Para os RHD/não-D, 47 foram RhD+ e RHD+/
RHCE+, e 3 foram RhD- e RHD-/RHCE+.
Para o Kell, 48 kk foram K2K2 e 2 Kk foram K1K2.
Para o Duffy, das 44 amostras que haviam sido
normais, GATA box, 8 Fy(a+b-) foram FYA/FYA,
15 Fy(a+b-) foram FYB/FYB e 19 Fy(a+b+) foram
FYA/FYB; das outras 4 amostras, 3 foram FYA/
FYB e heterozigoto GATA mutação, e 1 Fy(a-b-)
era FYB/FYB, homozigoto GATA mutação.
Duas amostras fenotipadas como Fy(a+b-), que
eram normais GATA, apresentavam as mutações
265T/298
A
 e 2 amostras fenotipadas como Fy(a-
b+) haviam sido genotipadas como FYA/FYB.
Para o Kidd, 15 Jk(a+b-) foram JKA/JKA, 12 Jk(a-
b+) foram JKB/JKB, e 20 Jk(a+b+) foram JKA/
JKB. Três amostras fenotipadas como JK(a+b+)
haviam sido genotipadas como JKB/JKB.
A genotipagem é mais acurada que a
fenotipagem para determinação de grupos
sangüíneos em pacientes portadores de β
talassemia politransfundidos. A genotipagem
nesses pacientes pode ser importante para
selecionar hemácias antigenicamente negativas
para transfusão de glóbulos vermelhos.
Rev.bras.hematol.hemoter., 2000, 22(2): 69-76
Palavras-chave: Genotipagem, grupos
sanguínios, sistema
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